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resumo A inserção de um cateter intravenoso periférico (CVP) é um dos procedimentos 
invasivos mais frequentemente realizados em ambiente hospitalar. No entanto, 
os CVPs falham correntemente antes da conclusão do tratamento intravenoso e 
aquando da sua inserção o risco de infeção aumenta exponencialmente. 
Existem poucos estudos que avaliam a contaminação deste dispositivo médico 
vascular e que caracterizam os microrganismos associados quanto à produção 
de fatores de virulência e resistência aos antimicrobianos. 
Neste estudo fomos avaliar a contaminação microbiana de CVPs, identificando 
os microrganismos mais prevalentes e estudando os seus fatores de virulência 
e resistência a antibióticos. 
Um total de 110 pontas de CVPs foram analisadas usando a metodologia de 
Maki et al. e microrganismos foram identificados. Staphylococcus spp. foram 
posteriormente estudados quanto ao perfil de susceptibilidade aos 
antimicrobianos pelo método de difusão em disco e com base no fenótipo de 
cefoxitina foram ainda classificados em estirpes resistentes à meticilina. Foi feito 
também um screening para o gene mecA por PCR e MIC-Vancomicina 
determinado por e-test, testou-se a atividade proteolítica e hemolítica em placa 
de Skim milk a 1% e gelose de sangue, respetivamente. A formação de biofilme 
foi avaliada em microplaca com leitura através de cloreto de iodonitrotetrazólio 
(INT). 
Cerca de 30% dos CVPs estavam contaminados e o género mais prevalente foi 
Staphylococcus spp., 48.8%. Este género apresentou resistência à penicilina 
(91%), eritromicina (82%), ciprofloxacina (64%) e cefoxitina (59%). Detetou-se 
59% de estirpes resistentes à meticilina e presença do gene mecA em 82% dos 
isolados testados. Relativamente aos fatores de virulência, 36.4% apresentaram 
α-hemólise e 22.7% β-hemólise, 63.6% produziam proteases e 63.6% 
apresentaram capacidade de formar biofilme. É de salientar que 36.4% dos 
isolados foram simultaneamente resistentes à meticilina e apresentaram 
expressão de proteases e/ou hemolisinas, formação de biofilme and MIC para 
vancomicina superiores a 2µg/mL. 
Deste modo, o nosso estudo evidenciou contaminação de CVPs principalmente 
por Staphylococcus spp, com elevada patogenicidade demonstrada pela 
presença de fatores de virulência, assim como resistência a antibióticos. A 
produção de fatores virulência permite fortalecer a adesão e a permanência dos 
microrganismos no cateter. Ao associarmos ainda a resistência aos 
antimicrobianos, o tratamento de infeções relacionadas torna-se mais difícil e as 
opções de tratamento escassas. Estes dados devem ser considerados pelos 
profissionais de saúde que devem adotar medidas preventivas para 
minimização do risco de contaminação e consequente redução das infecções 
relacionadas ao uso de cateteres intravenosos periféricos. 
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abstract The insertion of a peripheral intravenous catheter (PIVC) is one of the most 
frequently performed invasive procedures in the hospital setting. However, 
PIVCs usually fail before the completion of intravenous treatment and upon 
insertion the risk of infection increases exponentially. There are few studies 
evaluating the contamination of this vascular medical device and characterizing 
the associated microorganisms regarding the production of virulence factors and 
antimicrobial resistance. 
A total of 110 PIVCs ends were analyzed using the Maki et al. methodology and 
microorganisms were identified. The Staphylococcus spp. were subsequently 
studied for the antimicrobial susceptibility profile by disc diffusion method and 
based on the cefoxitin phenotype were further classified into strains resistant to 
methicillin. A screening for the mecA gene was also done by PCR and MIC- 
vancomycin as determined by E-test, proteolytic and hemolytic activity on Skim 
milk 1% plate and blood agar, respectively. The biofilm formation was evaluated 
on microplate reading through iodonitrotetrazolium chloride 95% (INT). 
About 30% of PIVCs were contaminated and the most prevalent genus was 
Staphylococcus spp., 48.8%. This genus presented resistance to penicillin 
(91%), erythromycin (82%), ciprofloxacin (64%) and cefoxitin (59%). Thus, 59% 
of strains resistant to methicillin were detected. We detected the mecA gene in 
82% of the isolates tested. Regarding the virulence factors, 36.4% presented 
hemolysis and 22.7% hemolysis, 63.6% presented a positive result for the 
production of proteases and 63.6% presented a biofilm formation capacity. About 
36.4% were simultaneously resistant to methicillin and showed expression of 
proteases and/or hemolysins, biofilm formation and MIC for vancomycin greater 
than 2µg/mL. 
Thus, our study evidenced contamination of PIVCs mainly by Staphylococcus 
spp., with high pathogenicity demonstrated by the presence of virulence factors, 
as well as resistance to antibiotics. The production of virulence factors allows to 
strengthen the attachment and the permanence in the catheter. When we also 
associate antimicrobial resistance, the treatment of the related infections 
becomes more difficult and the scarce treatment options. These data should be 
considered by health professionals who must take preventive measures to 
minimize the risk of contamination and consequent reduction of infections related 
to the use of peripheral intravenous catheters 
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1. Background 
 
 
The healthcare associated infections (HAIs) and the rapid adaptation of 
microorganisms through the expression of virulence factors and of antimicrobial 
resistance mechanisms are problems of growing importance worldwide (3,5). The 
medical devices have been identified as potential vehicles of microorganisms 
dissemination in an hospital environment, being often involved in the etiology of 
HAIs (5). 
 
This is of concern when it comes to the need for insertion of a medical device, 
such as the peripheral intravevous catheter (PIVC), which gives access to the 
bloodstream, thus increasing the risk of infection associated with these devices 
(6,7). 
 
 
1.1. Peripheral Intravenous Catheter (PIVC) 
 
In healthcare, the majority of the patients admitted in a hospital requires 
intravenous therapy (8–11). There are several types of vascular access devices in 
use, such as central venous catheter (CVC), peripheral intravenous catheter (PIVC), 
peripherally inserted central catheter (PICC) and midline catheter. It is estimated 
that 2 billion of PIVCs are sold in the worldwide, being considered the most common 
type of vascular access device used in hospital settings (10–16). 
 
PIVC is a small and flexible tube inserted in a peripheral vein, mainly the 
metacarpal, cephalic or basilica vein and secured to the skin with an adhesive 
dressing (11,12,17). They are typically made of polyurethane or silicone and its size 
can range from 26 to 14 Gauge (G) (11,12). This medical device is ideally suited for 
short-term use, up to 72-96 h, mainly for delivery of intravenous fluids and drugs 
(11,17,18). 
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The peripheral venous catheterization procedure is one of the most invasive in 
hospitalized patients, being inherent several local and systemic complications, such 
as thrombophlebitis, phlebitis, infiltration, catheter occlusion and catheter- 
associated bloodstream infection (6,10,11,13,15,16,19–23). These complications 
lead to the catheter failure before the end of intravenous treatment, can lead to 
increased mortality, morbidity and costs for healthcare system, prolonged care and 
hospitalization (9,11,13,19,20,23). 
 
1.2. Catheter-Related Bloodstream Infections (CRBSIs) 
 
 
The insertion of a vascular access devices is a potential pathway for the entry of 
microorganisms into the bloodstream, which can lead to the catheter-related 
bloodstream infections (CRBSIs) (6,7,17). However, some recent studies showed 
that the PIVC-related bloodstream infections (PIVC-RBSIs) rates (0.1%, 0.5 per 
1000 catheter-days) are lower than the other intravascular devices, such as CVC 
(4.4%, 2.7 per 1000 catheter-days) and PICC (2.4%, 2.1 per 1000 catheter-days) 
(14,24,25). Despite this, the rates of PIVC-RBSIs may rise in the future due to the 
wide use of PIVCs (8,25,26). These are still responsible for 5% (670 per 100.000 
patients) of nosocomial bacteraemia, being implicated in the aetiology of HAIs (25– 
27). 
 
For the occurrence of CRBSIs, three pathways are described for the entry of 
microorganisms through the medical device from a non-sterile external environment 
into the normally sterile bloodstream (27–29). The first, is called extraluminal, where 
the migration of microorganisms occurs mainly from the patient's skin into the 
catheter tract. This process may occur during the insertion of the catheter or while 
the catheter is in situ, however it is the most common route of infection for short- 
term catheters. The second route is called intraluminal, involving direct 
contamination of catheter hubs and connectors by contact with the hands of health 
professionals who handle it, contaminated fluids or devices. The third contamination 
route is when the catheter is contaminated by microorganisms circulating in the 
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bloodstream, when there is already a preexisting infectious condition responsible 
for the contamination of the device (26,27). 
 
These medical devices provide a surface area to which microorganisms can 
attach (27). The most common microorganisms involved are Staphylococcus 
species, namely coagulase-negative staphylococci (CoNS), predominantly S. 
epidermidis and S. aureus (25–27,30–33). Although these are commensal bacteria 
of the human skin and considered non-pathogenic, they have been recognized as 
relevant opportunistic pathogens (26,31,33). Others microorganism have been 
identified as the Gram-negative bacilli, Enterococcus spp. and fungi, such as 
Candida species (25,26,30,31). 
 
Some of these microorganisms are associated with the hospital-acquired 
infections through the cross-contamination between health professionals/medical 
devices and the patients mainly due the incorrect disinfection technique of the 
catheter insertion site, poor hand hygiene practices and inefficient device 
maintenance (5,7,28,31). 
 
 
1.3. Staphylococcus genus associated to PIVC-RBSIs 
 
The Staphylococcus genus emerges as the main etiological agent of infections 
through vascular access devices. Given the increasing use of PIVCs and the global 
threat represented by the increase in antibiotic resistance and the virulence of these 
microorganisms, the treatment of these infections becomes difficult, prolonged and 
ineffective (3,34,35). 
 
 
1.3.1. Virulence factors in Staphylococcus spp. 
 
Staphylococcus species are the most common causes of indwelling device– 
associated infections and nosocomial and community acquired infections due to 
their biofilm-forming properties as well virulence factors (Table I) (3,34–36). 
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Table I. Virulence factors of Staphylococcus spp.. Adapted and modified from Diaz R. 
(2018) (3). 
Mechanisms Virulence Factors 
 
 
 
Involved in evading/destroying host 
defenses 
Microcapsule protein A coagulase 
Fatty acid – metabolizing enzyme 
Leukocidin and/or g-toxin 
 
Proteases 
 
 
Involved in tissue invasion/penetration 
Nucleases 
Lipases 
Hyaluronate lyase staphylokinase 
 
 
 
Involved in toxin-mediated disease and/or 
sepsis 
Toxic shock syndrome toxin 
Enterotoxins 
Cytolytic toxins (a, b, g, and d) 
 
 
Toxic shock syndrome toxin 
 
Induce specific toxinosis Enterotoxin 
Exfoliative tox 
Attach to endothelial cells and basement 
membrane 
Binding proteins for fibrinogen, 
fibronectin, laminin, collagen 
 
 
 
1.3.1.1. Biofilm formation 
 
 
The biofilm that anchors to abiotic or biotic surfaces is a multicellular 
agglomeration with a characteristic three-dimensional structure and with its own 
physiology, also dependent on the microorganisms present and the 
microenvironment (1,35,36). This matrix is constituted by polysaccharides, teichoic 
acids, extracellular DNA (eDNA), staphylococcal proteins and other components 
(1,35). When the microorganisms are exposed to stress conditions, the virulence 
genes expression, such as biofilm formation is induced as a survival strategy 
(34,35). 
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The mechanism of biofilm formation is complex and multifactorial, which has 
three major phases known as: the attachment, maturation and detachment (Figure 
1) (1,35,36). 
 
Figure 1. Biofilm formation cycle. From Reffuveille F. et al. (2017) (1). 
 
 
1.3.1.1.1. Attachment 
 
 
In any case, the adhesion of the microbial cells to a surface is essential. This 
phase is initially reversible and may become irreversible, and is the first step to the 
maturation of a future biofilm. Staphylococcal adherence depends mainly of the 
surface components, physico-chemical structure of the medical device (hydrophobic 
and electrostatic interactions, hydrodynamic forces and temperature), 
environmental factors and serum or tissue protein adsorption in the case of biotic 
surface (1,35). 
 
The attachment of these gram-positive bacteria to the biotic surface, as human 
matrix proteins (fibronectin, fibrinogen, collagen and vitronectin), is due to specific 
interactions mediated by cell wall-anchored (CWA) proteins (1,34–36). The 
adhesins, better known as microbial surface components recognizing adhesive 
matrix molecules (MSCRAMMs) are one of the major groups of CWA proteins (37). 
MSCRAMMs have a common structure with 3 domains: binding domain, cell wall 
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spanning domain and domain responsible for covalent or non-covalent attachment 
of MSCRAMMs proteins to the bacterial surface. Covalent attachment is catalyzed 
by sortases which recognizes a conserved motif of the MSCRAMMs, called LPXTG 
motif. The variability of this type of molecule is higher in S. aureus compared to S. 
epidermidis. In addition to these, there are other molecules involved in this process 
as the several members of the serine-aspartate repeat family (Sdr proteins) and 
accumulation-associated protein (Aap). The non-covalent attachment of 
MSCRAMMs proteins to the surface of staphylococci is not well understood, but 
there is some evidence to suggest that autolysins are non-covalently attached to the 
teichoic acids. These proteins, present in great abundance in Staphylococcus 
species, have an important role in cell wall turnover and also have binding sites for 
human matrix proteins (1,36). 
 
In addition to the ability to bind to human proteins, staphylococci can also adhere 
to a plastic surfaces (abiotic). The main molecules involved are teichoic acids (TA), 
adhesins and autolysins. TA are composed by glycerol or ribitol phosphate polymers 
covalently linked to the peptidoglycan through the phosphodiester bond to the C6 
hydroxyl of the of N-acetyl muramic acid sugars. These may be covalently attached 
to the cell wall teichoic acid (WTA) or to the cell membrane through a lipid anchor 
known as lipoteichoic acid (LTA) (36,38). They are commonly found in Gram- 
positive bacteria, as is the case of S. aureus and S. epidermidis and has an 
important role in attachment to the plastic surfaces due to its interaction with other 
surface polymers. Therefore, TA have shown great importance not only in adhesion 
to a surfaces but also in the formation of the biofilm in species such as from 
Staphylococcus genus (1,36,38). 
 
Other molecules are adhesins such as the cell wall-bound surface protein Bap 
and SasC a S. aureus surface protein that are involved in the adherence to a 
polystyrene surface. In addition to the functions of the autolysins aforementioned, 
they also have the ability to attach to plastics (1,35). 
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This ability to bind to a plastic was the basis of most in vitro biofilm studies 
performed on staphylococci. However, its role in the infection associated with 
medical devices is not clarified because soon after its insertion these devices are 
rapidly covered by host matrix proteins preventing the direct interaction of teichoic 
acids to plastic. It is believed that these interactions are overestimated in vitro 
assays (1,34,36). 
 
 
1.3.1.1.2. Maturation 
 
After the attachment to a surface, the biofilm maturation phase starts, 
characterized by intercellular aggregation and structuring three-dimensional and 
multicellularity. This phase is regulated by the increase of bacterial mediators, the 
slowdown of metabolism and of cell cooperation (1,35,36). 
 
Initially, the fixed bacteria induce the biofilm process and potentiate intercellular 
aggregation in which adhesive proteins or usually polysaccharide-based - 
exopolymers intervenes. In staphylococci, polysaccharide intercellular adhesion 
(PIA), also known as poly-N-acetylglucosamine (PNAG), is the most described 
adhesive biofilm molecule and represents the major part of the extracellular matrix 
commonly called “slime”. This has a very important role in the organized community 
construction and is composed of exopolysaccharides (EPS), proteins, TA and eDNA 
(1,35,36,39). 
 
The PIA is encoded by an accessory gene cluster called the intercellular 
adhesion (ica) operon, which comprises an N-acetylglucosamine transferase (icaA 
and icaD), a PIA deacetylase (icaB), a putative PIA exporter (icaC) and a regulatory 
gene (icaR) (1,34–36,39,40). Its biosynthesis is regulated by a variety of 
environmental factors and regulatory proteins. The PIA functions as a glue that 
binds bacterial cells one to each other as well as on surface by electrostatic 
interactions. This happens through its deacetylation, in particular beta-1-6-linked N- 
acetylglucosamine residues, which introduce a positive charge to the surface of the 
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negatively charged of the bacterial cell, releasing free amino groups making the pH 
neutral or acid characteristic of the natural habitat of Staphylococcus (1,35,36,39). 
 
Despite being recognized as a key factor in virulence and biofilm formation of 
Staphylococcus, however it has been demonstrated that it is not expressed in all 
strains isolated from biofilm-associated infections suggesting that other compounds 
may be involved in this process (1,34–36). 
 
In the mechanisms of biofilm formation independent of PIA, other adhesive 
proteins can replace the PIA. Thus, the molecules already recognized as essential 
are: Aap, extracellular matrix binding protein (Embp), protein A, fibrinogen- binding 
proteins (FnbpA and FnbpB) or S. aureus surface protein G (SasG). Of these, the 
Aap, 220 kDa, appears to be the key molecule in biofilm formation independent of 
PIA, namely in S. epidermidis and in biofilm maturation by interactions with PIA, as 
in S. aureus. However, it only has the ability to induce biofilm formation when it is 
cleaved by proteases. SasG is responsible for intercellular aggregation to proteins 
present in other bacterial cells by hydrophilic interaction. Also, the SasC protein, 
anchored in the cell wall by having an LPXTG motif, and Bap protein both present 
in S. aureus, above referenced are also involved in intercellular aggregation and 
maturation of the biofilm. A homologous bap protein, named bhp was found in 
clinical isolates of S. epidermidis and it seems to contribute to a biofilm formation in 
this bacterial species. Particularly, in S. aureus the D-alanylation process of the TA 
is considered a very important process for the biofilm formation (1,35,36). 
 
The three-dimensional structure typically is a “mushrooms” shape or “towers” 
containing fluid channels essential for the delivery of nutrients to the multiple layers 
of the biofilm and it is characteristic of a mature biofilm (1,35,36). 
 
In this phase of biofilm structuring, staphylococci produce surfactant peptides, 
such as phenol-soluble modulins (PSMs) that are regulated by the global regulatory 
quorum sensing system through the accessory gene regulator (Agr). This was 
described for the first time by Seymour Klebanoff in 1999 as pro-inflammatory 
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“complex” agents in S. epidermidis. Two types of PSMs according to their length are 
described type α (~ 20-25 amino acids) and type β (~ 43-45 amino acids). The 
sequence is variable between species, but all have an amphipathic α-helix. The 
enhanced relative production of β-type PSMs over α-type PSMs seems to be one 
of the crucial factors in the biofilm maturation (volume, thickness, roughness and 
channel formation), as shown in S. epidermidis. Despite this differential production 
of PSMs, the mechanism by which this happens is still not understood (1,35,36,41). 
 
Other important molecules for the biofilm structure are amyloid proteins, which 
confer stability to the matrix, through the binding of their fibers to the eDNA (1,27,34– 
36,42). As above mentioned, the Bap protein is also required at this stage for the 
formation of amyloid-like aggregates, taking into account environmental conditions 
such as calcium concentration and pH (1,35,36). 
 
The enzymatic activity is fundamental for the occurrence of developmental and 
interruption events essentials during the biofilm maturation. Enzymes that degrade 
PIA (PIAse) and other proteases are the most important. The recognition of the 
importance of PIAse in this step, they have never been found in staphylococci. On 
the other hand, evidence of the role of proteases in the PIA independent pathway 
has already been demonstrated, namely in the development and detachment of the 
biofilm. These enzymes are mainly regulated by the quorum sensing (1,35,36). 
 
 
1.3.1.1.3. Detachment 
 
This last phase called detachment allows the bacterial survival and 
prolongation/progression of the disease. Thus, the mechanism of rupture of a 
mature biofilm is crucial for the systemic dissemination of bacteria, in single cells or 
clusters of larger cells into the bloodstream (1,35,36,43). 
 
This process can occur in two pattways: active or passive mode. The active 
dispersion is based on mechanical forces such as blood flow, corosion and human 
intervention. On the other hand, the passive dispersion refers to the process of 
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detachment induced by bacteria themselves that constitute the biofilm in response 
to some environmental stimulus. This pathway occurs with the production of 
enzymes (proteases, nucleases, among others) and PSMs that will degrade 
structural elements of the extracellular matrix, namely proteins, eDNA and 
exopolysaccharides (1,35,36,43). 
 
As we can see, molecules that act as biofilm structuring agents are also involved 
in their rupture when their rate of production is increased. This mechanism is 
controlled by the Agr system, mainly expressed in bacteria from the outer most 
layers of the biofilm, but is also necessary in deeper layers for the formation of the 
channels (1,35,36,43). 
 
 
1.3.1.2. Quorum-Sensing (QS) regulating the biofilm formation 
 
 
Bacteria have a regulatory system that allow the adaptation to environmental 
conditions such as the quorum sensing (QS) system (3,44). This is highlighted as 
one of the most important in the control of pathogenesis through the synchronization 
of genetic expression in the establishment of phenotypes such as virulence, biofilm 
formation and antibiotic resistance. In species of Staphylococcus, the main system 
responsible for the regulation of biofilm formation is the Agr, previously mentioned 
(1,3,35,44,45). 
 
From the agr locus of 3.5 kb, two primary transcripts, RNAII and RNAIII, are 
generated, whose transcription is directed by the promoters P2 and P3, respectively. 
The P2 operon encodes four agrB, agrD, agrC and agrA genes and P3 operon 
encodes hld gene for δ-hemolysin (δ- PSM) (1,35,44). 
 
The autoinducing peptide (AIP) is formed by 7-9 amino acids and contains a 
characteristic ring of thiolactone between the centrally located cysteine and the C- 
terminus and encoded by agrD transcript. The transmembrane endopeptidase, 
encoded by the agrB gene, is involved in the modification of propeptide through 
cyclic thiolactone bond between an internal cysteine and the carboxyl terminus and 
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also in the exportation of AIP to the extracellular medium, where it is cleaved by 
SspB type I signaling peptidase. The accumulation of extracellular AIP is to be 
detected by the histidine kinase domain of AgrC. After peptide binding to AgrC, the 
signal transduction cascade is activated, with histidine kinase phosphorylating 
which in turn regulates AgrA activity (response regulator). Upon being 
phosphorylated by AgrC, AgrA becomes active and is able to bind to the promoter 
region P2 and P3, as well as to the promoters that control the expression of the 
peptides PSMα and PSMβ (Figure 2) (1,2,35,44). 
 
Figure 2. Representation of the Staphylococcus spp. accessory gene regulatory (agr) 
system. The agr locus is known to contain two divergent transcripts named RNAII and 
RNAIII. The RNAII transcript is an operon of four genes, agrBDCA, that encode factors 
required to synthesize AIP and activate the regulatory cascade. Briefly, AgrD is the 
precursor peptide of AIP, AgrB is a membrane protease involved in generating AIP, AgrC 
is a histidine kinase that is activated by binding AIP, and AgrA is a response regulator that 
induces transcription of RNAII and RNAIII through the P2 and P3 promoters, respectively. 
AgrA also directly promotes PSM production. The RNAIII transcript yields a regulatory RNA 
molecule that acts as the primary effector of the agr system by up-regulating extracellular 
virulence factors and down-regulating cell surface proteins. From Novick RP. (2003) (2). 
 
 
The agr-QS regulator system is activated in response to cell density allowing the 
expression of virulence factors. During the initial phase of biofilm formation, the agr- 
quorum detection activity is weak and the surface proteins, MSCRAMMs, are highly 
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expressed to allow attachment. On the other hand, in the early stationary growth 
phase, these molecules are downregulated and Agr activity increases. There are 
also an overexpression of toxins and virulence factors, such as lipases, proteases 
and hemolysin. In the latter phase, upregulation of PSMs expression is required to 
promote bacterial dispersion (1–3,35,44). 
 
The biofilm structure, regulated by QS, provides several advantages to bacteria 
capable of producing it by creating a selected microenvironment, protecting them 
from the action of antibiotics, biocides and physical challenges, and allowing the 
development of the stress response (33,34,45). 
 
 
1.3.2. Antibiotic resistance in Staphylococcus spp. 
 
The rapid acquisition of resistance by Staphylococcus spp. becomes a problem 
in the treatment of human infections caused by this microorganism. The most 
worrying and emerging resistances in this genus are methicillin and more recently 
vancomycin (3). 
 
Methicillin was the first molecule of semi-synthetic β-lactam to be synthesized 
and introduced into clinical practice. Only differs from penicillin G in the substitutions 
at positions 2’ and 6’ of the benzene ring by methoxy groups, causing steric 
hindrance around the amide bond (46,47). 
 
Vancomycin was the first glycopeptide antibiotic to be developed (48). It was 
discovered by Eli Lilly in the 1950s, when an organism, called Amycolatopsis 
orientalis, produced a brown colored substance that inhibited gram-positive 
organisms, becoming known as "Mississippi mud" (2,54,55). The structure is based 
on a central, relatively conserved heptapeptide domain in which five of the seven 
amino acid residues are common to all glycopeptides. They differ only in amino 
acids at positions 1 and 3 and in the substituents of the aromatic amino acid residues 
(48). 
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Although they are of different classes, both antibiotics have action in the 
synthesis of the cellular wall, namely in the synthesis of peptidoglycan (3,49). 
 
 
1.3.2.1. Methicillin resistant Staphylococcus spp. 
 
 
In 1959, the methicillin was introduced in response to increased resistance to 
penicillin G developed by some Staphylococccus strains (3,50). However, as early 
as the following year, the first reports of methicillin-resistant strains will be emerging. 
As a result of these reports, methicillin-resistant S. aureus (MRSA) appears as a 
nosocomial pathogen that is still very common worldwide until today (3,51). 
 
 
1.3.2.1.1. Mechanism of resistance to methicillin 
 
 
The major structural component of the bacterial cell wall is peptidoglycan. This 
is constituted by glycan strands made of repeating N-acetylglucosamine and N- 
acetylmuramic acid disaccharides linked by peptide cross-links between N- 
acetylmuramic acid moieties on adjacent strand. In staphylococci, cell wall 
biosynthesis begins with the β-1,4-glycosidic bond of the N-acetylglucosamine 
disaccharides and N-acetylmuramic acid of the reducing end of the growing 
peptidoglycan chain in a transglycosylation reaction. The incorporated repeating 
unit is cross-linked by a transpeptide reaction to a stem peptide in an adjacent 
peptidoglycan chain. Both the transglycosylation reaction as well as the 
transpeptidation reaction are performed by penicillin-binding proteins (PBPs), which 
are the target of β-lactams. In gram-positive bacteria, the typical composition of the 
stem peptide is L-Ala-γ-D-Glu-L-Lys-D-Ala-D-Ala, variable between species (3,52). 
 
Penicillin binding protein 2a (PBP2a), is encoded by the acquired mecA gene 
located in the staphylococcal cassette chromosome mec (SCCmec). These 
enzymes are susceptible to β-lactam antibiotic modification, leading to inhibition of 
bacterial cell wall biosynthesis and bacterial death. In the absence of a β-lactam 
antibiotic, MecI represses the transcripts of mecA and mecR1-mecI. If present, 
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MecR1 is cleaved automatically and the metalloprotease domain, located in the 
cytoplasmic domain of MecR1, becomes active. This metalloprotease cleaves MecI 
allowing transcription of mecA and production of PBP2a (Figure 3) (3,53). 
 
Figure 3. Model of the salient features of mecA regulation. (A) Absence of β-lactams: the 
binding of the repressor MecI to this region stops transcription from the mec operator. (B) 
Presence of β-Lactams: are detected by their binding to the PBD of MecR1. MecR1 is 
autocatalytically cleaved and the metalloprotease domain becomes active. This MPD, which 
is bound to the mecA, cleaves MecI allowing the transcription of mecA and the production 
of PBP2a. From Diaz R. (2018) (3). 
 
 
Briefly, resistance to β-lactam antibiotics occurs as follows: they will function as 
analogs of the side chain substrates of peptidoglycan D-Ala-D-Ala, on which PBPs, 
such as PBP2a, act. Consequently, they form a long-acting covalent acyl-enzyme 
complex between β-lactam and the nucleophilic serine of the active site of PBP, 
inhibiting the transpeptidation step of cell wall biosynthesis. Thus, the deacylation 
of this complex is prevented because the active region accommodating the acceptor 
portion of dissociation or a potential hydrolysis water molecule is occupied by the β- 
lactam ring structure. PBPs are irreversibly inactivated because they lack 
regeneration capacity and the cross-linking phase of the cell wall is compromised, 
forming a defective wall that leads to cellular death (3,52). 
 
 
1.3.2.1.2. SCCmec mobile resistance element 
 
 
Pathogenic microorganisms have the ability to spread, create ecological 
reservoirs, colonize and cause disease. Mobile genetic elements, such as genomic 
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islands, bacteriophages, pathogenicity islands, chromosomal cassettes, plasmids, 
insertion sequences and transposons, have a key role in the dissemination of 
resistance and virulence (3,53). 
 
Resistance to methicillin is conferred by a genetic element which is integrated 
into a resistance island known as SCCmec. This DNA fragment (between 15 and 
60 kb) is located near the replication origin of the Staphylococcus chromosome and 
inserted at the insertion site attB downstream of an open reading frame (ORF), 
designated orfX. Each SCCmec element carries a complex of the mec gene and the 
ccr gene (3,53–55). 
 
The mec gene complex, in addition to the mec genes (mecA, mecB, mecC), also 
carries the genes that control its expression: mecR1 (encodes a signal transducing 
protein MecR1) and mecI (encodes a MecI repressor protein). The ccr gene 
complex is composed of ccr genes (ccrA, ccrB and ccrC) and ORFs. It acts on the 
specific integration, orientation and excision of SCCmec by ccrAB and/or ccrC (8 
allotypes). Furthermore, to these two essential complexes, this mobile element also 
has non-essential regions called J regions (Junkyard-region), namely J1, J2 and J3. 
Currently, eleven types of SCCmec are known, taking into account the variations in 
the different regions that constitute it (Figure 4) (3,53–56). 
 
 
 
Figure 4. SCCmec is bracketed by direct repeats (DRs) that contain integration site 
sequence (ISS). A pair of inverted repeats (IRs) is present at the termini of SCCmec. Two 
critical gene complexes, ccr and mec are present, and the other regions are designated J1, 
J2, and J3. From Diaz R. (2018) (3). 
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The mecA gene was first identified in S. aureus, but since it is located in a mobile 
genetic element able of exchanging genetic information between strains, this gene 
has also been identified in several Staphylococcus species, such as S. epidermidis, 
S. haemolyticus, S. saprophyticus, S. fleurettii and among others (53,54). 
 
 
1.3.2.2. Vancomycin resistant Stpahylococcus spp. 
 
 
In 1958, vancomycin was approved for use by the Food and Drug Administration 
(FDA) in the USA and introduced into the clinic for the treatment of gram-positive 
bacteria (3,57,58). With the emergence of methicillin-resistant strains in both CoNS 
and S. aureus, vancomycin became the gold standard in the treatment of infections 
caused by these bacteria (3,48,57,59,60). 
 
 
1.3.2.2.1. Mechanism of vancomycin action 
 
 
Although vancomycin inhibits cell wall synthesis by binding to the active site of 
the transpeptidase of PBPs as in β-lactam antibiotics, the mechanism of action is 
different. In this case, vancomycin binds to the C-terminal D-Ala-D-Ala residue of 
the peptidoglycan precursor, forming a stable non-covalent complex which blocks 
the use of the precursor for the synthesis of the cellular wall. This complex is 
characterized by several hydrogen bonds between the peptidic component of 
vancomycin and the D-Ala-D-Ala residue. Vancomycin does not penetrate the 
cytoplasm, acting outside the cytoplasmic membrane at a late-stage of 
peptidoglycan biosynthesis (Figure 5) (3,4,48,57). 
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Figure 5. Peptidoglycan biosynthesis and mechanism of action of vancomycin. Binding of 
the antibiotic to the C-terminal d-Ala–d-Ala of late peptidoglycan precursors prevents 
reactions catalyzed by transglycosylases and transpeptidases. From Courvalin P. (2006) 
(4). 
 
 
1.3.2.2.2. Mechanism of resistance to vancomycin 
 
 
The activity of vancomycin is determined by the substrate specificity of the 
enzymes that determine the structure of peptidoglycan precursors. The presence of 
operons encoding enzymes leads to resistance to vancomycin. These enzymes are 
involved in the modification and removal of vancomycin-binding target: the C- 
terminal d-Ala residues are replaced by d-lactate (d-Lac) or d-serine (d-Ser), with 
the synthesis of precursors with low affinity and then eliminate the high affinity 
precursors normally produced by the host (3,4). 
 
There are six types of vancomycin resistance: VanA, B, C, D, E and G, 
characterized in phenotypic and genotypic bases in enterococci. The localization of 
the various genes is different: the vanA and vanB operon can be found on plasmids 
or on the chromosome, while the vanC, vanD, vanE and vanG operons were still 
only found on the chromosome (3,4). 
 
Currently, only the VanA-type has been detected in S. aureus. This type is 
characterized by high levels of resistance to vancomyne and teicoplanin. It is 
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mediated by transposon Tn1546 (11-kb) encoding 9 polypeptides distributed in 
different functional groups: transposition (ORF1 and ORF2), regulation of gene 
expression of resistance (VanR and VanS), d-Ala-d-Lac depsipeptide synthesis 
VanH and VanA) and hydrolysis of peptidoglycan precursors (VanX and VanY) 
(3,4). 
 
Target modification begins with reduction of pyruvate to d-Lac by dehydrogenase 
(VanH) and the formation of an ester bond between d-Ala and d-Lac catalyzed by 
VanA-ligase. Substitution of the d-Ala-d-Ala dipeptide by the d-Ala-d-Lac 
depsipeptide formed in the peptidoglycan synthesis results in a considerable 
decrease in the affinity of the molecule for glycopeptides. VanX D,D-dipeptidase and 
VanY D,D-carboxypeptidase enzymes are involved in the removal of the d-Ala- 
terminated susceptible precursors, preventing the interaction of vancomycin with its 
target. VanX hydrolyzes the d-Alad-Ala dipeptide synthesized by the host d-Ala-d- 
Ala-ligase (Ddl) and VanY removes the C-terminal d-Ala residue of late 
peptidoglycan precursors when the elimination of d-Ala-d-Ala by VanX is incomplete 
(Figure 6) (3,4). 
 
 
 
Figure 6. VanA-type glycopeptide resistance. From Diaz R. (2018) (3). 
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2. Aims 
 
 
The insertion of a PIVC may potentiate the development of a bloodstream 
infection associated with this device. On the other hand, the microorganisms 
involved in these infections often express virulence factors and antimicrobial 
resistance profiles, often making it difficult to treat these infections. Despite this, it is 
important to point out the small number of studies that characterize these 
microorganisms, from their identification, production of virulence factors and 
antimicrobial resistance profile. 
The aim of this study was to evaluate the microbial contamination of PIVCs used 
in the peripheral catheterization procedure, identifying the most prevalent 
microorganisms and evaluating risk associated with these contaminations as seen 
by evaluating their virulence factors and antibiotic resistance. 
 
In addition, the specific objectives: 
• To isolate the most abundant species and their identification; 
• To evaluate the extracellular enzymes production: hemolysins and 
proteases; 
• To evaluate the ability to the biofilm formation; 
• To evaluate the antibiotic susceptibility profiles; 
• To detect the methicillin resistance and screnning of the mecA gene; 
• To determine the vancomycin-MIC. 
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3. Material and Methods 
 
 
 
3.1. Sample characterization 
 
The present study was performed in a service of a large tertiary hospital in the 
central region of Portugal. It had the approval of the Ethics Hospital Committee 
(reference number 0226/CES) and the authorization number 14037/2017 from the 
Portuguese Data Protection Authority. The patients’ written informed consent was 
obtained, respecting the Helsinki Declaration. 
A total of 110 PIVCs ends (2 cm) were collected and were storaged in sterile 
flasks at 4ºC, until the microbiological analysis at Coimbra Health School, 
Polytechnic Institute of Coimbra. 
 
 
3.2. Microbiological analysis 
 
 
3.2.1. Isolation and identification 
 
The PIVCs ends samples were inoculated on Columbia agar base 
(supplemented with 5% of sheep blood), using the technique of Maki et al. (61). The 
cultures were incubated at 37ºC in the normal atmosphere during 18h-24h. After 
enumeration and macroscopic evaluation, we performed the isolations of the 
macroscopically different microorganisms in Tryptic Soy Agar. 
Pure colonies obtained were characterized by the Gram staining and 
biochemical tests as catalase and/or oxidase to a primary identification. 
Subsequently, we used biochemical identification galleries as API Staph (REF 
20500) bioMérieux®, API 20 Strepto (REF 20600) bioMérieux®, API 20 NE (REF 
20050) bioMérieux®, API 20 E (REF 20100) bioMérieux®, following the 
manufacturer's instructions. The identification to the species was obtained using the 
Apiweb software as well as the score of identification. 
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3.2.2. Detection of extracellular enzymes 
 
3.2.2.1. Proteases 
 
The extracellular proteases production was determined by the plate assay in 
Luria Bertani (LB) (Merck, Darmstad, Germany) agar medium supplemented of 1% 
of skim milk (w/v). A bacterial suspension of 0.5 McFarland was prepared and 
subsequently inoculated (5μL), then all plates were incubated at 37 ˚C during 24h 
at normal atmosphere. The presence of extracellular proteases was revealed by the 
formation of clear halos around the colonies which were measured. The halos were 
classified as negative (-) in the absence of halo, as weak positive (+/-) in the 
presence of halo less than 11 mm, as positive (+) in the presence of halo less than 
13mm and as stong positive (++) in the presence of halo less than 15mm (62). 
 
3.2.2.2. Hemolysins 
 
The hemolytic activity was determined by the plate assay using a Columbia Agar 
with 5% sheep blood (Merck, Darmstad, Germany). A bacterial suspension of 0.5 
McFarland was prepared and subsequently 5μL was inoculated and plates 
incubated at 37˚C for 24h at normal atmosphere. The production of hemolysins was 
identified by the presence of clear (β-hemolysis) or diffuse (α-hemolysis) halos 
around the colonies (63). 
 
3.2.3. Biofilm formation assay 
 
From a 0.5 McFarland bacterial suspension, 10μL was inoculated into a 
multiwell (of 96 wells) plate with 100μL of Luria Bertani Broth (5 replicates for each 
strain were done) and the incubation was performed at 37 °C overnight with normal 
atmosphere. The planktonic cells were transferred and 25μL of 0.2 g.L-1 
iodonitrotetrazolium chloride 95% (INT) solution was added. Cells from biofilms 
were washed from multiwells with 200μL of phosphate buffered saline (PBS 1x) to 
remove all non-adherent cells and this process was repeated more 2 times. A 100μL 
of fresh media was added to the correspondent wells after rinsing followed by the 
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addition of 25μL of 0.2 g.L-1 INT solution. Both plates were immediately covered with 
aluminum foil and incubated in the dark at 37ºC. The reading was performed at λ: 
492nm after 30 min of incubation using the microplate reader (Thermo Fisher 
Scientific, USA). The biofilm formation results were normalized using the ratio of 
adherent cells at OD492nm / planktonic cells at OD492nm. The isolates which have 
values below 0.75 were classified moderate biofilm-formers, values between 0.75 
and 1.0 were classified high biofilm-formers, values above 1.0 were classified very 
high biofilm-formers (64). 
 
3.2.4. Antimicrobial susceptibility test: disk diffusion method 
 
The evaluation of the antimicrobial susceptibility profile of the isolates obtained 
was performed by disk diffusion method (modified Kirby-Bauer's test). From the 
fresh and pure culture, a suspension of 0.5 McFarland in sterile NaCl 0.9% was 
obtained and then inoculated in Muller Hinton agar. The selection of antimicrobial 
disks for Staphylococcus spp. took into account its clinical application: cefoxitin (30 
μg), ciprofloxacin (5 μg), chloramphenicol (30 μg), erythromycin (15 μg), gentamicin 
(10 μg), penicillin (10 units), tetracycline (30 μg) and trimethoprim-sulfamethoxazole 
(1.25/23.75 μg) (Table II). 
 
Table II. Classes of antibiotics and antibiotics tested for Staphylococcus isolates. 
 
Class Antibiotic 
 
Penicillinase-stable penicillins Cefoxitin 
 
Fluoroquinolones Ciprofloxacin 
 
Phenicols Chloramphenicol 
 
Macrolides Erythromycin 
 
Aminoglycosides Gentamicin 
 
Penicillinase-labile penicillins Penicillin 
 
Tetracyclines Tetracycline 
 
Folate pathway antagonists Trimethoprim-sulfamethoxazole 
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The antibiograms were incubated in normal atmosphere at 37ºC for 18-24h. The 
reading was based in the inhibition halos (mm) measurement, and phenotypically 
the strain was classified as sensitive, intermediate and resistant. The interpretation 
of the results was performed taking into account the Clinical and Laboratory 
Standards Institute (CLSI, 2018) (65). 
The detection of methicillin resistance was also performed, based on the 
reading of the inhibition halo to cefoxitin, taking into account CLSI standards (65). 
 
3.2.5. Determination of susceptibility to vancomycin by E-test method 
 
The susceptibility to vancomycin was performed by the E-test method with the 
determination of the minimum inhibitory concentration (MIC). From the fresh and 
pure culture, a suspension of 0.5 McFarland in sterile NaCl 0.9% was obtained and 
then inoculated in Muller Hinton agar. The antibiograms were incubated in normal 
atmosphere at 37ºC for 18-24h. The interpretation of the results was performed 
according to CLSI, 2018 (65). 
 
 
3.3. DNA extraction 
 
A bacterial cell suspension, with one pure colony, in LB medium, was incubated 
overnight at 37°C. After, the inoculum was centrifuged for 10 min at 13000g, then 
the supernatant was discarded and the pellet resuspended in 200µL of Tris-EDTA 
(TE). The DNA extraction was made using the GeneJET Genomic DNA Purification 
Kit #K0721 (Thermo Fisher Scientific, USA) following the manufacturer instructions. 
The DNA solution obtained was stored at -20ºC. 
 
 
3.4. Detection of mecA gene using PCR technique 
 
The mecA gene amplification was performed by PCR using specific primers: 
mecA-R (5’-CAATTCCACATTGTTTCGGTC-3’) and mecA-F (5’- 
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GAAATGACTGAACGTCCGATA-3’) (Metabion International AG, Germany). The 
primers used were designing using the nucleotide sequence databases from NCBI. 
Amplification was done using 12.5μL DreamTaq PCR Master Mix (2X) (Thermo 
Scientific, EUA), 10pmol of the forward and the reverse primers, 9.5μL of the 
nuclease-free water and 1μL of the bacterial DNA. The PCR reactions were 
performed using a MyCycler Thermal Cycler (Bio-Rad, USA). The amplification 
conditions consisted of an initial denaturation step (95 °C for 5 min), followed by 30 
amplification cycles consisting of denaturation (94 °C for 45 seg), annealing (53ºC 
for 45 seg) and extension (72°C for 1 min) and a final extension step (72°C for 10 
min). The DNA of a positive and negative strains to mecA gene were used as a 
positive and negative controls previously characterized and provided by a hospital. 
The reaction products were separated by electrophoresis on a 1.5% (w/v) agarose 
gel. All gels were run in 1×TAE buffer at 80V for 80min, stained in 0.5μgmL−1 of 
ethidium bromide solution and the images were acquired with the Gel Doc XR+ 
System (Bio Rad, California). 
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4. Results 
 
 
4.1. Prevalence of the PIVCs microbiological contamination and 
identification of the isolates 
The study population had, on average, 79 years with a standard deviation of ± 
11 years. At 110 PIVCs ends, 30% were contaminated from which 45 
macroscopically different isolates were obtained. The most prevalent genus was 
Staphylococcus spp. in 48.8%. Belonging to this genus, isolated bacterial species 
were S. aureus, S. epidermidis, S. haemolyticus, S. lentus, S. warneri and S. 
xylosus. Other clinically relevant microorganisms were found as Enterococcus spp., 
Escherichia coli, Klebsiella pneumonia and Stenotrophomonas maltophilia. The 
remaining 40% corresponded to other microorganisms whose identification was not 
possible (Table III). 
In 8.2% of the infected PIVCs, more than one isolate was observed. 
 
 
Table III. Prevalence of isolated microorganisms in PIVCs. 
 
Isolated Microorganisms Isolates Prevalence (%) 
S. aureus 12,17 4.4 
 
S. epidermidis 
4-7,11,13-  
26.7 
 15,18,20-22  
Staphylococcus spp. S. haemolyticus 2,8-10,19 11.1 
S. lentus 3 2.2 
S. warneri 16 2.2 
S. xylosus 1 2.2 
Enterococcus spp.  4.4 
Escherichia coli  2.2 
Klebsiella pneumonia  2.2 
Stenotrophomonas 
maltophilia 
  
2.2 
Others  (molds, yeasts 
and not other bacteria) 
  
40 
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4.2. Virulence factors in Staphylococcus isolates: proteolytic and hemolytic 
activity and biofilm formation 
 
Concerning proteases production, the majority of the isolates displayed a 
positive phenotype. However, 40.9% of the isolates presented higher levels of 
proteolytic activity (Table IV). 
 
Table IV. Proteolytic activity in Staphylococcus isolates. 
 
Protease Production Isolates Prevalence Rates (%) 
 
- 1-3,8,11,12,17,22 36.4 
 
+/- 6,9,13-15 22.7 
 
+ 4,5,7,10,18,19,21 31.8 
 
++ 16,20 9.1 
 
 
In the haemolytic activity different phenotypes were observed, some strains were 
negative (40.9%), 36.4% presented α-hemolysis and 22.7% presented β-hemolysis 
(Table V). 
 
Table V. Hemolytic activity in Staphylococcus isolates. 
 
Hemolytic Activity Isolates Prevalence Rates (%) 
- 1,3,7,13-16,20,21 40.9 
α-hemolysis 4-6,18,22 36.4 
β-hemolysis 2,8-12,17,19 22.7 
 
All strains demonstrated the ability to produce biofilm, with ratios ranging from 
capacity 0.45 to 1.7. However, it was found that the majority (63.8%) had high to 
very high capacity (Table VI, Figure 7). It was also observed that of this majority, 
50% of the isolates correspond to S. epidermidis. 
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Figure 7. Bacterial cell culture in microplate showing the biofilm cells after INT incubation; 
1 – Higher ability to form a biofilm; 2 – Moderate ability to form a biofilm; 3 – Lower ability 
to form a biofilm. 
 
Table VI. Biofilm formation in Staphylococcus isolates. 
 
Ratio of adherent/planktonic 
cells 
 
Isolates 
 
Prevalence Rates (%) 
< 0.75 + 3,8-10,12,15,17,19 36.4 
≥ 0.75 – < 1 ++ 2,7,13,16,20-22 31.8 
≥ 1 +++ 1,4-6,11,14,18 31.8 
 
4.3. Antibiotic resistance in Staphylococcus isolates: susceptibility profile 
and presence of mecA gene 
The main resistances found among Staphylococcus isolates were penicillin 
(91%), erythromycin (82%), ciprofloxacin (64%) and cefoxitin (59%). The 
antimicrobial agents for which they presented greater sensitivity (showing a largest 
halos) were ciprofloxacin (95%), tetracycline (86%), gentamicin (73%) and 
trimethoprim-sulfamethoxazole (59 %) (Figure 8). 
1 
2 
3 
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Susceptible Intermediate Resistance 
 
Figure 8. Antibiotic susceptibility profile of Staphylococcus isolates; TE – Tetracycline; 
STX – Trimethoprim-Sulfamethoxazole; CN – Gentamicin; CIP – Ciprofloxacin; C – 
Chloramphenicol; FOX – Cefoxitin; P – Penicillin; ERY – Erythromycin. 
 
According with CLSI (2018) we found 59% of methicillin resistance in 
Staphylococcus isolates (65). However, when we evaluated the presence of the 
genetic determinant mecA among methicillin resistant isolates, putatively enconding 
PBP2a, we found 82% of positive strains (Figure 9). 
 
 
Figure 9. Genotypic profiles in Staphylococcus isolates; MW – Molecular Weight; 1,2,4 and 
5 – Staphylococcus isolates positive to the presence of the mecA gene; 3 - Staphylococcus 
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isolates negative to the presence of the mecA gene; PC – Positive Control and NC – 
Negative Control. 
 
Relatively to the vancomycin susceptibility profile, we found sensitivity in all 
isolates, according the CLSI classification and had been into account the identifition 
as S. aureus or CoNS (65). However, when we observed the MIC levels of 
sensitivity, the majority of the isolates presented values higher than to 2μg/mL 
(Table VII, Figure 10). 
 
 
Figure 10. Example of vancomycin-sensitive isolates with differents MIC, where (A) has 
MIC ≥ 2 μg/mL and (B) MIC < 2 μg/mL. 
 
Table VII. Antibibiotic susceptibility profile: MIC-Vancomycin. 
 
MIC-Vancomycin (μg/mL) Isolates Prevalence Rates (%) 
< 2 2,8,11,12,17,19,20,21 36.4 
≥ 2 1,3-7,9,10,13-16,18,22 63.6 
 
In addition, it is noted that about 45.5% of methicillin-resistant staphylococci 
(MRS) and 9.1% methicillin susceptible staphylococci (MSS) has MIC for 
vancomycin greater than 2μg/mL. 
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5. Discussion 
 
 
The present investigation was carried out in order to act at prevent level PIVCs 
related infections, with evaluation of the contamination of the devices, identification 
of the microorganisms, as well as to study some of its virulence factors and 
antimicrobial resistance. 
In this study it was verified that 30% of the analyzed PIVCs were contaminated. 
We consider this rate very relevant, given the high use of this medical device in a 
hospital context. Some of the variables to be considered with a significant impact on 
the contamination of these devices are the degree of compliance with aseptic care 
during insertion and maintenance, the number of manipulations, the type of dressing 
applied in their fixation and their length of stay (66). However, there are no pre- 
existing studies in this field, there are only studies that report the rate of infection of 
the bloodstream associated with PIVCs. In these studies rates of infection were 
varied, ranging from 35 to 70% (30,67). In this present study the preexisting 
infectious condition, responsible for the contamination of the device, can not be 
discarded, since this variable was not controlled. 
Regarding the identified microorganisms, it was verified that the most prevalent 
genus was Staphylococcus in 48.8%, predominantly CoNS (44.4%), of which S. 
epidermidis was the most common (27.7%). Also in these studies the genus 
Staphylococcus is responsible for 58% of the infections caused by PIVCs, of which 
about 25% are coagulase negative (25,30). Other identified microorganisms 
belonging to this genus were also found in the present investigation: S. aureus, S. 
haemolyticus, S. lentus, S. warneri and S. xylosus. 
The presence, even punctual, of Enterococcus spp., E. coli, Klebsiella 
pneumoniae and Stenotrophomonas maltophilia was also observed. The low 
incidence can be explained by the fact that they are not part of the normal microbiota 
of the skin, however the presence of these microorganisms in a hospital 
environment can allow their presence in a transient microbiota (26). However, we 
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highlight the relevance of these microorganisms found in the context of HAIs as 
opportunistic pathogens (3). There are reports of studies on the presence of these 
species associated with PIVCs infections also with low prevalence (25,26,68). 
 
The presence of more than one isolate occurred in 8.2% of contaminated PIVCs, 
this result being similar to that found by Guembe et al. which found only 2.9% of 
PIVC-RBSI polymicrobials episodes (68). 
The fact of the higher prevalence of S. epidermidis in this medical devices can 
be due to it´s commensal feature of the human skin that can be associated with 
procedures during the insertion and manipulation of PIVC that can lead to an 
infection. In addition, these microorganisms produce virulence factors involved in 
processes such as attachment to the catheter with increased expression of TA, 
adhesins and autolysins and to the human matrix with increased expression of 
MSCRAMMs and tissue invasion with the production of extracellular enzymes such 
as proteases and hemolysins (1–3,35,44). This fact justifies the results obtained in 
this study for the proteolytic and hemolytic activity of the isolates, in which protease 
production was observed in 40.9%, α-hemolysis production in 36.4%. 
After adaptation to the catheter, the production of biofilm by these 
microorganisms is quite common, as verified in 63.8% of the studied isolates that 
revealed high capacity of biofilm production. In addition, one of the species that 
demonstrated to have this capacity was S. epidermidis in 50% of the isolates. This 
microorganism is described as the major nosocomial pathogen associated with 
implanted medical device infections due to its ability to form the extracellular 
polysaccharide membrane which allows its own protection and strengthens 
attachement to the catheter (33,34). The investigation by Hashem et al. shows that 
55% of S. epidermidis associated with CRBSI are biofilm producers, being in 
agreement with the one observed in our study (69). 
Due to the protective nature of the biofilm, associated bacteria are intrinsically 
resistant to many antibiotics, which can increase up to 1000 times. The main 
reasons for this may be the difficulty of biofilm penetration by antibiotics, low growth 
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rate of bacteria and the presence of antibiotic degradation mechanisms (70,71). In 
addition, biofilm promotes horizontal gene transfer between bacteria, causing the 
spread of drug resistance determinants and other virulence factors (70,72). This 
association has already been demonstrated by some studies, such as Belbase et 
al. and Ghasemian et al., who found higher rates of resistance to multiple drugs and 
resistance to methicillin in biofilm producing strains compared to non-biofilm 
producing strains (70,73). The present study corroborated this information, with 59% 
of isolates being methicillin resistant Staphylococcus and 82% of strains positive for 
the presence of the mecA gene. The presence of this genetic determinant in the 
majority of the isolates suggests the propensity for the dissimination of resistance 
genes between bacteria living in biofilm, as evidenced by other studies (33,70,73). 
Kitao et al. also indicates that an increase of S. epidermidis resistant to methicillin 
with the presence of the mecA gene and capable of biofilm formation has occurred 
in many cases of CRBSIs (33). 
In addition, isolates of Staphylococcus spp. studied have an antimicrobial 
multiresistance profile: penicillin (91%), erythromycin (82%), ciprofloxacin (64%) 
and cefoxitin (59%). This type of profile leads to difficulties in treatment, resulting in 
prolonged treatment, extended duration of hospital admission, development and 
persistence of chronic infectious diseases in local and/or distant organs, or even 
mortality (33). 
When methicillin resistance was detected in Staphylococcus spp., the 
glycopeptide antibiotics, such as vancomycin, were selected as gold standard for 
the treatment of serious infections caused by these microorganisms. However, it 
was observed a slow but steady increase in vancomycin MIC in recent years (3). 
Although in this study all the isolates showed a sensitivity profile to vancomycin. Yet, 
it is noted that 63.6% presented values higher than 2μg/mL, which are close to an 
intermediate phenotype. Thus, this result is in agreement with the study conducted 
by Cherifi et al. who also did not observe any resistance to this antibiotic 
glycopeptide (74). In clinical context, vancomycin is used as the treatment of choice 
and the last resort for infections caused by Staphylococcus spp.. However, its 
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excessive intravenous use has allowed the adaptation of these microorganisms, 
causing strains with greater sensitivity to vancomycin (3). 
 
It is noted that 36.4% of the strains showed methicillin resistance, MIC- 
vancomycin greater than 2μg/mL, the ability to produce at least one extracellular 
enzyme and biofilm production. This is rather worrying when we think that these 
highly adapted and virulent strains are in a catheter that has access to the 
bloodstream in an already immunocompromised patient. 
In this context, in order to minimize the contamination of PIVCs and consequent 
CRBSIs, health professionals should have an active role, through proper hand 
hygiene before, during and after any procedure associated with peripheral venous 
catheterization, to take preventive measures during to the insertion and 
maintenance of these medical devices. Other authors have already mentioned that 
this control is very relevant with regard to the minimization of infections related to 
vascular medical devices, as is the case of PIVCs (7,25,26,75). 
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6. Conclusions 
 
 
This study is innovative at a preventive level, in the sense that the risk associated 
with the use of PIVCs was evaluated, one of the most frequently used devices in 
healthcare, and may play an important role in HAIs. 
This investigation allowed to identify the microorganisms relevant to colonizing 
PIVCs, to know their profile of antimicrobial susceptibility and their virulence factors. 
It was verified that the main microorganisms found belong to the genus 
Staphylococcus. CoNS were the most prevalent, with the presence of S. epidermidis 
in 27.7%. In fact, these microorganisms are able to remain in the catheter, often due 
to failures of hand hygiene of health professionals, usually nurses, and failures in 
insertion and maintenance of the device. 
In addition, they produce virulence factors such as proteases, hemolysins and 
biofilm that facilitate their adhesion and permanence in the catheter, often leading 
to CRBSIs. Associated with these virulence factors, they develop resistance to 
antimicrobials, making it difficult to choose the trait and reducing the available 
therapeutic options. 
Since it is widely recognized that health professionals play an important role in 
the context of hospital infections and considering the high frequency of intravascular 
device insertion and the associated risks, it is urged to raise awareness of this 
problem so that new strategies can be tested preventive measures. 
For the future prevention of HAIs associated with PIVCs, we sensitize the 
scientific community for more extensive investigations, with more samples and with 
continuous characterization of the microorganisms. 
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